C. Vitae Jordi Monés 1 CURRICULUM VITAE, July, 2018 Jordi M. Monés PERSONAL DATA. 1. EDUCATION / QUALIFICATIONS 2. PRESENT PROFESSIONAL POSITIONS 3. PAST POSITIONS 4. INTERNATIONAL AWARDS 5. ADVISORY BOARDS and RESEARCH COMMITTEES 6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS 7. BASIC RESEARCH PROJECTS 8. CLINICAL TRIALS 9. SCIENTIFIC PUBLICATIONS 10. SCIENTIFIC PRESENTATIONS 11. GRANTS 12. TEACHING ACTIVITIES and INVITED LECTURES 13. COLLABORATION IN JOURNALS EDITION and REVIEWER 14. THESIS 15. SCIENTIFIC SOCIETIES MEMBERSHIP 16. LANGUAGES C. Vitae Jordi Monés 2 PERSONAL DATA: Name: Jordi Manel Monés i Carilla (Jordi M. Monés) Address: Institut de la Màcula Centro Médico Teknon Àrea Vilana. Building 90 Vilana 12, 08022 Barcelona SPAIN Telephone +34 93 5950155 Fax +34 93 5950345 E- mail: [email protected] Web: www.institutmacula.com Date of Birth: Barcelona, June 25, 1961. 1. EDUCATION / QUALIFICATIONS: 1.1. 09/1979 - 06/1985: LICENCIATE IN MEDICINE AND SURGERY. Qualification: Excellent. University of Barcelona. Barcelona, SPAIN. 1.2. 01/1986: SPANISH NATIONAL BOARD EXAMINATION for a Residency Position M.I.R.1985/6: National classification number: 84. 1.3. 1/86 - 12/1989: RESIDENCY IN OPHTHALMOLOGY, (Opthalmologist M.I.R.) Barraquer Institute, Barcelona, SPAIN. 1.4. 1/1990 - 06/1991: RESEARCH FELLOWSHIP IN OPHTHALMOLOGY (RETINA SERVICE). The Massachusetts Eye and Ear Infirmary, Harvard University. Boston, U.S.A. C. Vitae Jordi Monés 3 1.5. 07/1991 - 07/1992: SURGICAL VITREORETINAL FELLOWSHIP. CLINICAL AND SURGICAL RETINA FELLOWSHIP. Retina Department, Hospital San José. Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM). Monterrey, MEXICO. 1.6. 06/2010 - 06/2012: DOCTORAL THESIS, Ph.D. Degree. DOCTOR IN MEDICINE AND SURGERY, Qualification: Cum Laude. University of Barcelona, SPAIN. 2. PRESENT PROFESSIONAL POSITIONS: 2.1. CURRENT: 2.1.1. M.D., Ph.D., Opthalmologist, Macula and Vitreorretinal Specialist and Researcher. 2.1.1.1. Founder and Director of the Institut de la Màcula Centro Médico Teknon, Àrea Vilana, Building 90, Vilana 12, 08022 Barcelona, since 2007. 2.1.1.2. Director, principal investigator and one of the founders of the Barcelona Macula Foundation: Research for Vision, since 2011. 2.1.1.3. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon, since 2010 2.1.1.4. Institut de la Màcula i de la Retina Acredited site of the network of excellence in research, European Vision Institute www.europeanvisioninstitute.org/ 2.1.1.5. Member of the Steering Committee at the International Multicenter Clinical Trials Proxima A and Proxima B on Geographic Atrophy. Roche, Basel, Switzerland 2.1.1.6. Member of the Steering Committee at the International Multicenter Clinical Trials Brighter and Crystal. Novartis. C. Vitae Jordi Monés 4 2.1.2. Scientific Advisory Boards 2.1.2.1. Member of the Scientific Advisory Board of AMD international Alliance 2.1.2.2. Member of the Region Europe Ophthalmics Network (REONET) advisory board, Novartis 2.1.2.3. Member of the European Advisory Board on Retinal Vein Occlusion, ERAB, Allergan Inc 2.1.2.4. Scientific Advisor of Opththech Inc, New York USA 2.1.2.5. Scientific Advisor of Notalvision Inc, Tel Aviv, Israel 2.1.2.6. Member of the International Advisory Board for Eylea® (VEGF- Trap eye) Bayer Schering Pharma 2.1.2.7. Clinical Advisor of CellCure NeuroSciences Ltd. 2.1.3. Other positions: 2.1.3.1. Member of the Board of Directors of Futbol Club Barcelona and Responsible of the Medical Department and Performance from 2003- 2005, and 2010-2015. 2.1.3.2. Member of the Board of Directors, Comissioner FC Barcelona Universitas and Responsible for the Sport Sciences Department, 2015-2017. 2.1.3.3. Member of the National Council of Centre for Integration of Medicine and Innovative Technologies in Catalonia (CIMTI). November, 2017 3. PAST POSITIONS: Consultant as Vitreoretinal Specialist Ophthalmologist in: 3.1. Institut de Microcirurgía Ocular de Barcelona. (April 1993 -December 2006) C. Vitae Jordi Monés 5 3.2. Hospital de la Creu Roja de Barcelona (1995 - Nov 2004), Consultant Ophthalmology Service. Vitreoretinal Surgery. 3.3. Associate Profesor Universitat Autònoma de Barcelona in: (2003 - 2006) Cátedra (Professorship) Institut de Microcirurgia Ocular de Barcelona Universitat Autónoma de Barcelona 3.4. Member of the Board of Directors (Junta Directiva) of FUTBOL CLUB BARCELONA. Responsible of the Medical and Sport Medicine Department of Futbol Club Barcelona. June 03 - June 05 3.5. Elected Coordinator of the Specialty of Ophthalmology at the Centro Médico Teknon. Feb 10 - Feb 12 Main Fields of professional interests: His research particular fields of interest are macular diseases, choroidal neovascularization, macular degeneration, antiangiogenic therapy, anti PDGF therapy, geographic atrophy, retinal degeneration, retinal transplant, stems cells, gene therapy, macular edema, and vitreoretinal and macular surgery. 4. INTERNATIONAL AWARDS: 4.1. Co-Winner of the INTERNATIONAL AWARD OF EXPERIMENTAL SURGERY Banc de Sabadell, Acadèmia de Medecina de Barcelona, i Col.legi Oficial de Metges de Barcelona, with the Research Project: "Photodynamic Therapy of the Experimental Posterior Malignant Melanoma" (Massachusetts Eye and Ear Infirmary, Harvard University, Boston, USA. Director of the Project: Evangelos Gragoudas MD). Barcelona, June 18, 1991. 4.2. Premi a la Recerca Científica en DMAE. Associació Discapacitat Visual de Catalunya. 30 Novembre 2011 4.3. Academy's Achievement Award 2015. American Academy of Ophthalmology. C. Vitae Jordi Monés 6 5. ADVISORY BOARDS AND RESEARCH COMMITTEES 5.1. 1999: Rotating Member of Study Advisory Group of the “Randomized, Placebo-Controlled, Masked, Multicenter, Phase III b Study of the Treatment of the Subfoveal Neovascularization Secondary to Age-Related Macular Degeneration and pathologic myopia Using Photodynamic Therapy with Liposomal BPD-MA Verteporfin” Institut de Microcirurgia Ocular de Barcelona. 5.2. 2000: Rotating Member of Study Advisory Group of the “Photodynamic Therapy using Verteporfin Study VER, VIO and VIM”. Institut de Microcirurgia Ocular de Barcelona. 5.3. 2003: Member of the International Consultant Committee for Research in AMD, Novartis International, Basel, Switzerland. 5.4. 2003 – 2005: Member of the International Council for Research of Retinal Diseases of Eyetech Co. New York, USA 5.5. 2003 – Ongoing: Scientific Consultant of Notalvision, Co. Tel-Aviv, Israel. 5.6. 2003 – 2006: Member of the Macula Society Research Committee 5.7. 2008 Allergan advisory board. Annual Meeting Association for Research in vision and ophthalmology, Fort Lauderdale, USA. May 1-5 2008 5.8. 2008 Advisory Board Meeting Ophthotech for new treatments for exudative and Dry AMD London, 30 and 31 October, London 5.9. 2008 Advisory board Allergan for Posurdex device for the treatment of macular edema secondary to retinal vein occlusion and diabetic macular edema. American Academy of Ophthalmology, November 9. Atlanta, USA 5.10. 2008 Advisory Board for Preferential Hyperacuity Perimeter. Notalvision, Israel. 5.11. (from 2008 please see in section 13.2) C. Vitae Jordi Monés 7 6. COLLABORATIVE EUROPEAN RESEARCH PROJECTS 6.1. 2013- 2016: LITE: Laser imaging Techniques for the anterior and posterior eye. Institut de Ciències Fotòniques; Istituto Nazionale di Ottica; Istituto di Fisica Applicata Nello Carrara, Construzione Strumenti Oftalmici and Institut de la Màcula i de la Retina (Principal investigator in Catalonia Site). ERANET Biophotonics. European Comission Financed 6.2. 2015-2016: PRO4VIP: Innovative PROcurement for Visually Impaired People. European Pre-Commercial Public Procurement (PCP) and Innovative Public Procurement (IPP) project that forms part of the European Vision 2020 strategy. Coordinated by AQuAS (Generalitat de Catalunya), it enjoys the participation of the Barcelona Macula Foundation, together with 12 other institutions from England, the rest of Spain, Denmark, France and Italy. Financed by H2020. 6.3. 2015-Ongoing: EYE RISK. Exploring the combined role of genetic and non- genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK). Topic PHC-01-2014. Horizon 2020. Coordinated by Eberhard Karls Universitaet Tuebingen (EKUT), it enjoys the participation of the Barcelona Macula Foundation, together with 10 other institutions. Financed by H2020. 6.4. 2016- On going. ADVANCE.CAT. Accelerating Development ON Advanced Teraphies in Catalonia. RIS3CAT communities. The research and innovation strategy of Catalonia. Generalitat de Catalunya. Financed by FEDER source. 7. BASIC RESEARCH PROJECTS 7.1. 2012 - 2016: Principal Investigator, The geographic atrophy in pig study (the GAP study): A phase I escalating dose of subretinal sodium iodate: a toxic- induced animal model of geographic atrophy of RPE and photoreceptors. Institut de la Màcula i de la Retina, Barcelona Macula Foundation C. Vitae Jordi Monés 8 7.2. 2016- On going: Principal Investigator. Translational Research in regenerative stem cell therapies for retinal degenrative diseases from the swine animal model of retinal atrophy to clinical trials in human patients with age-related macular degeneration, retinitis pigmentosa and Stargardt’s disease. Barcelona Macula Foundation. Barcelona Macula Foundation (BMF), Centre de Medicina Regenerativa de Barcelona (CMRB), Banc de Sang i Teixitis (BSiT) and Fundación Leitat. 7. CLINICAL TRIALS 7.1. 1989: Principal Investigator